Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Comparable Ablation Efficiency of 30 and 100 mCi of I-131 for Low to Intermediate Risk Thyroid Cancers Using Triple Negative Criteria

  • Fatima, Nosheen (Department of Nuclear Medicine, Dr Ziauddin Hospital) ;
  • Zaman, Maseeh uz (Department of Nuclear Medicine, Dr Ziauddin Hospital) ;
  • Zaman, Areeba (Department of Nuclear Medicine, Dr Ziauddin Hospital) ;
  • Zaman, Unaiza (Department of Nuclear Medicine, Dr Ziauddin Hospital) ;
  • Tahseen, Rabia (Department of Nuclear Medicine, Dr Ziauddin Hospital)
  • Published : 2016.04.11
Download PDF
⟨ Previous Next ⟩

Abstract

Background: There is controversy about ablation efficacy of low or high doses of radioiodine-131 (RAI) in patients with differentiated thyroid cancers (DTC). The purpose of this prospective study was to determine efficacy of 30 mCi and 100 mCi of RAI to achieve successful ablation in patients with low to intermediate risk DTC. Materials and Methods: This prospective cross sectional study was conducted from April 2013 to November 2015. Inclusion criteria were patients of either gender, 18 years or older, having low to intermediate risk papillary and follicular thyroid cancers with T1-3, N0/N1/Nx but no evidence of distant metastasis. Thirty-nine patients were administered 30 mCi of RAI while 61 patients were given 100 mCi. Informed consent was acquired from all patients and counseling was done by nuclear physicians regarding benefits and possible side effects of RAI. After an average of 6 months (range 6-16 months; 2-3 weeks after thyroxin withdrawal), these patients were followed up for stimulated TSH, thyroglobulin (sTg) and thyroglobulin antibodies, ultrasound neck (U/S) and a diagnostic whole body iodine scan (WBIS) for ablation outcome. Successful ablation was concluded with stimulated Tg< 2ng/ml with negative antibodies, negative U/S and a negative diagnostic WBIS (triple negative criteria). ROC curve analysis was used to find diagnostic strength of baseline sTg to predict successful ablation. Results: Successful ablation based upon triple negative criteria was 56% in the low dose and 57% in the high dose group (non-significant difference). Based on a single criterion (follow-up sTg<2 ng/ml), values were 82% and 77% (again non-significant). The ROC curve revealed that a baseline sTg level ${\leq}7.4ng/ml$ had the highest diagnostic strength to predict successful ablation in all patients. Conclusions: We conclude that 30 mCi of RAI has similar ablation success to 100 mCi dose in patients with low to intermediate risk DTC. A baseline $sTg{\leq}7.4ng/ml$ is a strong predictor of successful ablation in all patients. Low dose RAI is safer, more cost effective and more convenient for patients and healthcare providers.

Keywords

References

  1. Barbaro D, Verburg FA, Luster M, Reiners C, Rubello D (2010). ALARA in rhTSH stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity? Eur J Nucl Med Mol Imaging, 37, 1251-4. https://doi.org/10.1007/s00259-010-1402-8
  2. Cooper DS, Doherty GM, Haugen BR, et al. (2006). Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 16, 1-33. https://doi.org/10.1089/thy.2006.16.1
  3. Fatima N, Zaman MU, Ikram M, et al (2014). Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers. Asian Pac J Cancer Prev, 15, 6443-47. https://doi.org/10.7314/APJCP.2014.15.15.6443
  4. Fatima N, Zaman MU, Zaman A, et al (2016). Factors predicting early release of thyroid cancer patients from the isolation room after radioiodine-131 treatment. Asian Pac J Cancer Prev, 17, 125-9. https://doi.org/10.7314/APJCP.2016.17.1.125
  5. Hackshaw A, Harmer C, Mallick UH, et al (2007). 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab, 92, 28-38. https://doi.org/10.1210/jc.2006-1345
  6. Haymart MR, Banerjee M, Stewart AK, et al (2011). Use of radioactive iodine for thyroid cancer. JAMA, 306, 721-8. https://doi.org/10.1001/jama.2011.1139
  7. Haugen BR, Alexander EK, Bible KC, et al (2016). 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 26, 1-133 https://doi.org/10.1089/thy.2015.0020
  8. Iyer NG, Morris LG (2011). Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer, 117, 4439-46. https://doi.org/10.1002/cncr.26070
  9. Maenpaa HO, Heikkonen J, VaalavirtaL, Tenhunen M, Joensuu H (2008). Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS One, 3, 1885. https://doi.org/10.1371/journal.pone.0001885
  10. Mallick U, Harmer C, Yap B, et al (2012). Ablation with lowdose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med, 366, 1674-85. https://doi.org/10.1056/NEJMoa1109589
  11. Pacini F, Schlumberger M, Dralle H, et al (2006). European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol, 154, 787-803. https://doi.org/10.1530/eje.1.02158
  12. Rubino C, de Vathaire F, Dottorini ME, et al (2003). Second primary malignancies in thyroid cancer patients. Br J Cancer, 89, 1638-44. https://doi.org/10.1038/sj.bjc.6601319
  13. Sawka AM, Thephamongkhol K, Brouwers M, et al (2004). Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab, 89, 3668-76. https://doi.org/10.1210/jc.2003-031167
  14. Sherman SI (2003). Thyroid carcinoma. Lancet, 361, 501-11. https://doi.org/10.1016/S0140-6736(03)12488-9
  15. Schlumberger M, Catargi B, Borget I, et al (2012). Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer. N Engl J Med, 366, 1663-73. https://doi.org/10.1056/NEJMoa1108586
  16. Zaman MU, Fatima N, Padhy AK, et al (2013). Controversies about radioactive iodine-131 remnant ablation in low risk thyroid cancers: are we near a consensus? Asian Pac J Cancer Prev, 14, 6209-13. https://doi.org/10.7314/APJCP.2013.14.11.6209

Cited by

  1. Decreasing Use of Radioactive Iodine for Low-Risk Thyroid Cancer in California, 1999 to 2015 vol.103, pp.3, 2017, https://doi.org/10.1210/jc.2017-02269